201 related articles for article (PubMed ID: 30829029)
1. Concentration-Dependent Dual Effects of Ciprofloxacin on SB-590885-Resistant BRAF
Aldaghi SA; Jalal R
Chem Res Toxicol; 2019 Apr; 32(4):645-658. PubMed ID: 30829029
[TBL] [Abstract][Full Text] [Related]
2. Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells.
Fratangelo F; Camerlingo R; Carriero MV; Pirozzi G; Palmieri G; Gentilcore G; Ragone C; Minopoli M; Ascierto PA; Motti ML
Int J Oncol; 2018 Sep; 53(3):1149-1159. PubMed ID: 29956724
[TBL] [Abstract][Full Text] [Related]
3. Onconase Restores Cytotoxicity in Dabrafenib-Resistant A375 Human Melanoma Cells and Affects Cell Migration, Invasion and Colony Formation Capability.
Raineri A; Fasoli S; Campagnari R; Gotte G; Menegazzi M
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31783660
[TBL] [Abstract][Full Text] [Related]
4. Metalloproteinases Suppression Driven by the Curcumin Analog DM-1 Modulates Invasion in BRAF-Resistant Melanomas.
de Souza N; de Oliveira ÉA; Faião-Flores F; Pimenta LA; Quincoces JAP; Sampaio SC; Maria-Engler SS
Anticancer Agents Med Chem; 2020; 20(9):1038-1050. PubMed ID: 32067622
[TBL] [Abstract][Full Text] [Related]
5. Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor.
Caporali S; Alvino E; Lacal PM; Levati L; Giurato G; Memoli D; Caprini E; Antonini Cappellini GC; D'Atri S
Int J Oncol; 2016 Sep; 49(3):1164-74. PubMed ID: 27572607
[TBL] [Abstract][Full Text] [Related]
6. Mefloquine induces ER stress and apoptosis in BRAFi-resistant A375-BRAF
Jandova J; Park SL; Corenblum MJ; Madhavan L; Snell JA; Rounds L; Wondrak GT
Mol Carcinog; 2022 Jun; 61(6):603-614. PubMed ID: 35417045
[TBL] [Abstract][Full Text] [Related]
7. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
8. NO-releasing STAT3 inhibitors suppress BRAF-mutant melanoma growth.
Kaoud TS; Mohassab AM; Hassan HA; Yan C; Van Ravenstein SX; Abdelhamid D; Dalby KN; Abdel-Aziz M
Eur J Med Chem; 2020 Jan; 186():111885. PubMed ID: 31784187
[TBL] [Abstract][Full Text] [Related]
9. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma.
Ma XH; Piao SF; Dey S; McAfee Q; Karakousis G; Villanueva J; Hart LS; Levi S; Hu J; Zhang G; Lazova R; Klump V; Pawelek JM; Xu X; Xu W; Schuchter LM; Davies MA; Herlyn M; Winkler J; Koumenis C; Amaravadi RK
J Clin Invest; 2014 Mar; 124(3):1406-17. PubMed ID: 24569374
[TBL] [Abstract][Full Text] [Related]
10. ER stress promotes antitumor effects in BRAFi/MEKi resistant human melanoma induced by natural compound 4-nerolidylcathecol (4-NC).
Alves-Fernandes DK; Oliveira ÉA; Faião-Flores F; Alicea-Rebecca G; Weeraratna AT; Smalley KSM; Barros SBM; Maria-Engler SS
Pharmacol Res; 2019 Mar; 141():63-72. PubMed ID: 30550954
[TBL] [Abstract][Full Text] [Related]
11. The first small molecules capable of strongly suppressing proliferation of cancer cells harboring BRAF class I/II/III mutations.
Choi SH; Shin I; Kim N; Nam Y; Sim T
Biochem Biophys Res Commun; 2020 Nov; 532(2):315-320. PubMed ID: 32873393
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy targeting the elevated interleukin-6 level reduces invasive migration of BRAF inhibitor-resistant melanoma cells.
Mohapatra P; Prasad CP; Andersson T
Mol Oncol; 2019 Feb; 13(2):480-494. PubMed ID: 30582770
[TBL] [Abstract][Full Text] [Related]
13. Degradation of AMPK-α1 sensitizes BRAF inhibitor-resistant melanoma cells to arginine deprivation.
Li YY; Wu C; Shah SS; Chen SM; Wangpaichitr M; Kuo MT; Feun LG; Han X; Suarez M; Prince J; Savaraj N
Mol Oncol; 2017 Dec; 11(12):1806-1825. PubMed ID: 29094484
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of novel thiobarbituric acid derivatives targeting both wild-type and BRAF-mutated melanoma cells.
Ramisetti SR; Pandey MK; Lee SY; Karelia D; Narayan S; Amin S; Sharma AK
Eur J Med Chem; 2018 Jan; 143():1919-1930. PubMed ID: 29133035
[TBL] [Abstract][Full Text] [Related]
15. AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
Wang H; Quan H; Lou L
Biochem Biophys Res Commun; 2017 Jul; 489(1):14-20. PubMed ID: 28536078
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
[TBL] [Abstract][Full Text] [Related]
17. The positive correlation between drug addiction and drug dosage in vemurafenib-resistant melanoma cells is underpinned by activation of ERK1/2-FRA-1 pathway.
Rao M; Shi B; Yuan Y; Wang Y; Chen Y; Liu X; Li X; Zhang M; Liu X; Sun X
Anticancer Drugs; 2020 Nov; 31(10):1026-1037. PubMed ID: 32868647
[TBL] [Abstract][Full Text] [Related]
18. A Fluoro Derivative of Embelin, as Potent B-RAF Inhibitor in Melanoma.
Babu A; Laila SP; Fernandez A
Anticancer Agents Med Chem; 2021; 21(15):2066-2074. PubMed ID: 33372883
[TBL] [Abstract][Full Text] [Related]
19. Light-controlled inhibition of BRAFV600E kinase.
Hoorens MWH; Ourailidou ME; Rodat T; van der Wouden PE; Kobauri P; Kriegs M; Peifer C; Feringa BL; Dekker FJ; Szymanski W
Eur J Med Chem; 2019 Oct; 179():133-146. PubMed ID: 31252305
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of a new series of highly potent RAF kinase-inhibiting triarylpyrazole derivatives possessing antiproliferative activity against melanoma cells.
Khan MA; El-Gamal MI; Tarazi H; Choi HS; Oh CH
Future Med Chem; 2016 Dec; 8(18):2197-2211. PubMed ID: 27845592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]